Explore the Agenda

7:00 am Check In, Morning Coffee & Light Refreshments

7:55 am Chair’s Opening Remarks

Contextualising the ADC Landscape & Leveraging Opportunities to Unlock Differentiation For the Future of Targeted Therapies

8:00 am Panel Discussion: Evaluating the Cutting-Edge Innovation & Performance Driving ADC Differentiation & Progression Earlier Line Patient Therapies

Chief Scientific Officer, Iksuda Therapeutics
Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D, AstraZeneca
Vice President, Research & Head, R&D Technology & Innovation, Amgen
Partner & Co-Founder, Genesis BioCapital
Chief Scientific Officer, Sutro Biopharma
Senior Vice President, Biotech Unit, BeOne Medicines
  • Understanding the 2026 ADC landscape and how the bar has been raised to develop and deliver differentiated ADCs with meaningful patient impact
  • Assessing the need for novel ADC chemistry innovation: What is showing the most promise across novel payloads and conjugation technologies?
  • Discussing the potential of novel ADC biology approaches across bispecific targeting and antibody engineering to unlock next generation ADC therapies
  • Highlighting methods to best pursue ADC clinical differentiation across patient selections methods, combination strategies, and well executed clinical design

9:00 am WuXi XDC: Technology Innovation & Global Expansion to Empower Bioconjugate Development from Concept to Commercialisation

Chief Executive Officer, WuXi XDC
  • Exploring WuXiDAR4 novel conjugation technology and payload linker platform to enable development of better ADCs with increased stability and a wider therapeutic index
  • Spotlighting the WuXi XDC Singapore Site: The cornerstone of global dual sourcing strategy
  • Highlighting integrated CRDMO solutions to empower bioconjugate development from concept to commercialisation

9:30 am The Next Generation of ADCs: Leveraging Novel Conjugation & Enhanced Antibody Engineering for the Future of Targeted Oncology Therapies

Executive Director & Head, Tumour Targeted Delivery Bioscience, Oncology R&D, AstraZeneca
  • Laying out the scope to differentiate ADC development through novel conjugation, antibody engineering, and target identification approaches to widen therapeutic index and bring patient benefit
  • Incorporating in silico and AI tools to enhance the ADC discovery toolbox and deliver next-generation ADC engineering and design
  • Highlighting future priorities for next-generation ADC development, including exploring the potential of radio conjugates

10:00 am Morning Break & Networking

Discovery

Discovery

Chair:

Partner & Co-Founder, Genesis BioCapital

Delving Into Rationale & Performance of Novel Payloads to Combat ADC Resistance

11:00 am Auristatin S: Developing an Auristatin Payload with Improved Tolerability & Modified Bystander Activity

Director, ADC Chemistry, Pfizer
  • Rationally designing Auristatin S to improve tolerability of auristatin payloads through the tuning of permeability and bystander activity
  • Explaining how Auristatin S maintains key auristatin properties including strong tubulin binding affinity and induction of immunogenic cell death
  • Exploring Austin S improved preclinical therapeutic window

11:30 am Harnessing ADC Design Strategies for Next-Generation AOCs

Chemistry Manager, Abzena
  • Expanding architecture of linker payload and conjugation modality for AOCs
  • Solving the challenges of next generation conjugates using Thiobridge® technology
  • Supporting characterisation and manufacture of bioconjugates through Abzena’s integrated offering

12:00 pm Evolving ADC Discovery to Design & Develop Next-Generation ADCs with Differentiated Therapeutic Profiles

Team Leader, Associate Fellow, GSK
  • Leveraging automation to improve efficiency and throughput for ADC discovery
  • Laying out the GSK approach and attitude to ADC discovery to ensure development of future ADC therapeutic impact
  • Highlighting novel linker-payload design approaches to improve ADC physicochemical properties and tumour targeting specificity

12:30 pm RenBiologics Accelerates the Development of Multi-Specific ADCs

Chief Scientific Officer, Biocytogen
  • Showcasing how Biocytogen provides a unique, fully characterised library of fully human antibody binders targeting over 1,000 druggable proteins
  • Unveiling how several bispecific ADC assets, utilising a common light chain and our proprietary Topo1 payload, are now in clinical trials
  • Exploring RenNano mice generate fully human nanobodies for next-generation ADC applications
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain

1:00 pm Lunch & Learn Session Presentation Hosted By Proveo

Invitation-only session. For all other attendees, lunch is provided in the exhibition area

Discovery

Is Two Better Than One? Investigating Dual Target & Dual Payload ADC Development

2:00 pm Fine-Tuning Next-Generation Bispecific ADCs for Improved Efficacy & Safety

Director, Biologics Core Technologies, SOTIO Biotech
  • Leveraging site-specific conjugation and linker-payload technologies to advance a pipeline of ADCs
  • Exploring preclinical development of bispecific ADCs aspiring to minimise on-target toxicity and overcome tumour heterogeneity
  • Optimising the bispecific format for optimal effect on tumour cells with varying antigen expression and discussing translation of functional in vitro data into in vivo efficacy

2:30 pm Contextualising Trifecta ADC Design & Advancing Next-Generation Branched Linker ADC Development

Head, ADC Research & Technologies, Debiopharm
  • Applying a trifecta approach to design a fit-for-purpose linker for haematologic ADCs, with preclinical insights from Debio-1562M incorporating MLINKSELECT DM1
  • Developing and implementing branched linker technology for next-generation dual payload ADCs in solid tumours
  • Recapping lessons learned in advancing high-DAR ADCs from discovery to the clinic

3:00 pm TME-Specific Payload Release: Discovery & Preclinical Validation of a Novel Enzyme-Cleavable Linker

Vice President, Antibody Discovery & ADC Platform, Nona Biosciences
  • Addressing tumour heterogeneity and drug penetration challenges with internalisation-independent payload release
  • Screening and identifying a unique linker using a specific TME enzyme expressed across cancer models for next-generation ADC development
  • Achieving superior efficacy and safety with an internalisation-independent linker-payload system in ductal and squamous carcinoma cell lines
Preclinical & Translational
Clinical Lessons
Process & Analytical Development
Manufacturing & Supply Chain

3:30 pm Afternoon Break & Networking

Scientific posters will be displayed all day. Use this dedicated time to meet poster authors and ask your burning questions

Spotlighting Late-Stage ADC Clinical Programmes Bringing Better Earlier Line Oncology Treatments to Patients in Need

4:30 pm From IND to Long Term Commercial Supply: A Step Ahead Against the Challenges of Bioconjugates

Head, Sales & Technical Business Development, BSP Pharmaceuticals
  • Serving the innovators from the candidate selection to the IND, from Phase I to the long-term commercial supply
  • Highlighting the approach to support early-stage programme through robust development studies
  • Overviewing conjugation and fill/finish capabilities
  • Delivering important updates on conjugation and fill-finish capacity

5:00 pm Belantamab Mafodotin Mechanism of Action: Explaining Induction of Immunogenic & Inflammatory Cell Death to Remodel the Tumour Microenvironment in Patients

Vice President, Translational Haematology & Tumour Omics, Oncology Translational Research, GSK
  • Highlighting the importance of in-depth translational characterisation of late-stage ADC assets to understand clinical success
  • Explaining how belantamab Mafodotin mechanism of action enables durable patient responses in the clinic
  • Laying out lessons learnt that can influence how subsequent and future ADCs are designed

5:30 pm Demonstrating Technical Excellence in Bioconjugate Development & Manufacturing

Group Lead, Process & Analytical Development, Merck
  • Introducing the techniques used during development to achieve deep process understanding and right first-time transfer to manufacturing
  • Exploring the established roadmap to scale up ADC manufacturing
  • Learning through case studies: seamless transfers from process and analytical development to GMP production

6:00 pm Exploring Clinical Profile & Approval Journey of EMRELIS Against Nonsquamous Non-Small Cell Lung Cancer With High c-Met Protein Overexpression

Executive Medical Director, Oncology, & Global Development Lead, AbbVie
  • Introducing rationale for targeting c-Met and breaking down Teliso-V design and development, including tandem companion diagnostic development against c-Met
  • Diving into Phase II LUMINOSITY safety and efficacy readouts on clinical outcomes in NSCLC patients that lead to FDA accelerated approval
  • Highlighting lessons learned from development journey in an indication without an approved ADC therapy, and understanding what this means for other ADC programmes

6:30 pm Chair’s Closing Remarks

6:30 pm Drinks Reception

7:30 pm End of Scientific Programme Day One